A lot of peptide claims trace back to one or two studies. Here’s a framework for judging how much weight a given paper can bear.
1. What model was used?
Roughly in order of how directly results translate to humans: in vitro (cells) → animal (usually rodent) → small human pilot → randomized controlled trial → multiple RCTs or meta-analysis. Plenty of compounds look great in rodents and do nothing in people.
2. How was it designed?
- Was there a control group, and was it appropriate?
- Were treatment and outcome assessment randomized and blinded?
- How big was the sample? Small n plus many outcomes makes a false positive likely.
- Was the primary outcome pre-specified, or picked after seeing the data?
3. Does the dose and route translate?
Animal doses don’t map linearly onto humans, and the route of administration (oral, injected, topical, local) changes pharmacokinetics a lot. Be cautious when a study’s dose or route is very different from what’s being discussed.
4. Has anyone else replicated it?
Independent replication from a different lab is one of the strongest signals available. A large literature from a single group is weaker than it looks.
5. Who funded it, and where was it published?
Funding and venue don’t decide whether a result is correct, but they’re context worth noting. Watch out for predatory journals.
When you share a paper, try to note which of these it does well or poorly. It makes discussions much more productive.